Kazia Therapeutics Ltd (KZIA) |
|
6.2 0.47 (8.2%)
|
08-13 16:00 |
|
Open: |
5.68 |
Pre. Close: |
5.73 |
|
High:
|
6.475 |
Low:
|
5.64 |
|
Volume:
|
262,911 |
Market Cap:
|
45M |
|
|
|
|
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is headquartered in Sydney, Australia. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.476 - 6.501 |
6.501 - 6.53 |
|
Low:
|
5.579 - 5.603 |
5.603 - 5.631 |
|
Close:
|
6.152 - 6.193 |
6.193 - 6.241 |
|
Technical analysis |
as of: 2020-08-13 4:35:54 PM |
|
Overall:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 9.57 One year: 11.17 |
| Support: |
Support1: 5.14 Support2: 3.25 |
| Resistance: |
Resistance1: 8.19 Resistance2: 9.57 |
| Pivot: |
4.72  |
| Moving Average: |
MA(5): 6.00 MA(20): 4.57
MA(100): 3.32 MA(250): 3.57 |
| MACD: |
MACD(12,26): 0.59 Signal(9): 0.40 |
| Stochastic oscillator: |
%K(14,3): 47.29 %D(3): 47.89  |
| RSI: |
RSI(14): 73.66 |
| 52-week: |
High: 9.74 Low: 2.27 Change(%): 160.5 |
| Average Vol(K): |
3-Month: 46170 10-Days: 237125 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.KZIA has closed below upper band by 10.4%. Bollinger Bands are 329.2% wider than normal. The large width of the bands suggest high volatility as compared to KZIA's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 13 Aug 2020
Is it Time to Dump Kazia Therapeutics Ltd (KZIA) Stock After it Is Higher By 42.15% in a Week? - InvestorsObserver
Tue, 11 Aug 2020
Kazia Therapeutics Limited (KZIA) investors to reap big returns again - Marketing Sentinel
Tue, 11 Aug 2020
74 Biggest Movers From Yesterday - Benzinga
Mon, 10 Aug 2020
Could Kazia Therapeutics Limited [KZIA] rocket further after FDA gives RPDD for Cancer Treatment? - newsbur.com
Fri, 07 Aug 2020
Kazia Therapeutics News: Why KZIA Stock Is Rocketing 43% Higher Today - InvestorPlace
Fri, 07 Aug 2020
Should You Buy Kazia Therapeutics Ltd (KZIA) in Biotechnology Industry? - InvestorsObserver
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Click here to get more fundamental analysis.
|
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ Capital Market |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
7 |
| Shares Float (M) |
4 |
|
% Held by Insiders
|
|
|
% Held by Institutions
|
3.56 |
|
Shares Short (K)
|
10 |
|
Shares Short P. Month (K)
|
6 |
Stock Financials |
|
EPS
|
-0.920 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
2.940 |
|
Profit Margin
|
|
|
Operating Margin
|
|
|
Return on Assets (ttm)
|
-25.9 |
|
Return on Equity (ttm)
|
-66.1 |
|
Qtrly Rev. Growth
|
-18.6 |
|
Gross Profit (p.s.)
|
0.213 |
|
Sales Per Share
|
|
|
EBITDA (p.s.)
|
|
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
|
|
Levered Free Cash Flow (M)
|
|
Stock Valuations |
|
PE Ratio
|
-6.74 |
|
PEG Ratio
|
|
|
Price to Book value
|
2.11 |
|
Price to Sales
|
|
|
Price to Cash Flow
|
|
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
